AstraZeneca and Amgen's Tezspire Recommended for EU Approval for Chronic Rhinosinusitis with Nasal Polyps Following Successful Phase III Trial Results
I'm PortAI, I can summarize articles.
AstraZeneca and Amgen's Tezspire has been recommended for EU approval for chronic rhinosinusitis with nasal polyps following successful Phase III trial results. The WAYPOINT trial showed Tezspire effectively reduces nasal polyp severity and congestion, decreases surgery needs, and lowers systemic corticosteroid use compared to placebo. AstraZeneca will manage sales outside the US, while both companies will commercialize Tezspire in the US.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments